A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2002
12/19/2002	WO2002078684A3 Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders
12/19/2002	WO2002078679A3 Succinimide and maleimide derivatives and their use as topoisomerase ii catalytic inhibitors
12/19/2002	WO2002076405A3 Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
12/19/2002	WO2002076388A3 Methods for increasing analgesic potency and attenuating adverse excitatory effects of bimodally-acting opioid agonists by inhibiting gm1-ganglioside
12/19/2002	WO2002074777A3 Pyranocoumarin compounds as a novel pharmacophore with anti-tb activity
12/19/2002	WO2002074236A3 Skin whiteners containing hydroxytetronic acid
12/19/2002	WO2002072544A3 Multifluoro-substituted chalcones and analogs as activators of caspases and inducers of apoptosis and the use thereof
12/19/2002	WO2002070561A3 Nuclear hormone receptor ligand binding domain
12/19/2002	WO2002070560A3 Nuclear hormone receptor ligand binding domain
12/19/2002	WO2002070558A3 Nuclear hormone receptor ligand binding domain
12/19/2002	WO2002070541A3 Peptide deformylase inhibitors
12/19/2002	WO2002070533A3 Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides
12/19/2002	WO2002070515A3 Chromane derivatives, process for their preparation and their use as antitumor agents
12/19/2002	WO2002069972A3 Triazole compounds and the use thereof in the prophylaxis and therapy of neurodegenerative diseases, cerebral trauma and cerebral ischemia
12/19/2002	WO2002067864A3 Coenzyme q products exhibiting high dissolution qualities
12/19/2002	WO2002066012A3 Amphoteric liposomes and the use thereof
12/19/2002	WO2002065981A3 Chemotherapeutic composition using calcium phosphate paste
12/19/2002	WO2002064087A3 Neurotherapeutic use of carboxypeptidase inhibitors
12/19/2002	WO2002060894A3 Sulfonamide lactam inhibitors of factor xa
12/19/2002	WO2002060462A3 Waay to obtain a extract with antidepressant and opioid antagonists properties and pharmaceutical products obtained from it
12/19/2002	WO2002060428A3 Methods of using and compositions comprising (-)sibutramine optionally in combination with other pharmacologically active compounds
12/19/2002	WO2002060421A3 Use of 2-amino-1(4-hydroxy-2-methanesulphonamidophenyl)ethanol for treating urinary incontinence
12/19/2002	WO2002059128A3 Process for preparing clopidogrel
12/19/2002	WO2002059080A3 Trisubstituted carbocyclic cyclophilin binding compounds and their use
12/19/2002	WO2002058705A3 Degradation-resistant glucocorticosteroid formulations
12/19/2002	WO2002058681A3 Use of rhein for preparing a medicine for treating a high level of il-1
12/19/2002	WO2002058672A3 Microparticles of biodegradable polymer encapsulating a biologically active substance
12/19/2002	WO2002058626A9 Methods and compositions for the identification and treatment of neurodegenerative disorders
12/19/2002	WO2002057222A3 Thiol-based naaladase inhibitors
12/19/2002	WO2002056878A3 Pharmaceutical composition having reduced tendency for drug crystallization
12/19/2002	WO2002055501A3 N-pyridyl carboxamide derivatives and pharmaceutical compositions containing them
12/19/2002	WO2002055085A3 Use of an adenosine a3 receptor agonist for inhibition of viral replication
12/19/2002	WO2002050082A3 Inhibitors of papilloma virus
12/19/2002	WO2002042248A3 Naphthalene derivatives
12/19/2002	WO2002029014A3 Stem cell differentiation-inducing promoter
12/19/2002	WO2001087301A9 Methods for treatment of inflammatory diseases
12/19/2002	WO2001068859A9 Il-17 receptor like molecules and uses thereof
12/19/2002	WO2001047919A9 Substituted oxazolidinones and their use in the field of blood coagulation
12/19/2002	WO2001041748A3 Pharmaceutical combinations and their use in treating gastrointestinal disorders
12/19/2002	WO2000058303A9 4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands
12/19/2002	US20020193875 Agent promoting the formation of skin basement membrane, agents promoting the formation of artificial skin and process for producing artificial skin
12/19/2002	US20020193855 Patient temperature regulation method and apparatus
12/19/2002	US20020193634 Disulfide derivatives useful for treating allergic diseases
12/19/2002	US20020193633 Mast cell stabilizers
12/19/2002	US20020193614 Treatment of cardiovascular disorders
12/19/2002	US20020193612 Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes
12/19/2002	US20020193609 Compounds and methods for use thereof in the treatment of cancer or viral infections
12/19/2002	US20020193603 Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
12/19/2002	US20020193601 Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
12/19/2002	US20020193600 Preparing anhydrous 4-(4-(4-(Hydroxydiphenylmethyl)-1-piperidinyl)-1-hydroxybutyl)-alpha,alpha- dimethylbenzene acetic acid hydrochloride by azeotropic distillation of the corresponding hydrate
12/19/2002	US20020193597 3-(heteroarylamino) indazole, 1,2-benzisothiazole, or 1,2-benzisoxazole derivatives of given formula; for treating nervous system disorders such as pain, anxiety and bipolar disorder
12/19/2002	US20020193595 Agonists of the melanocortin-4 receptor ("MC-4r"); useful treating obesity and type 2 diabetes
12/19/2002	US20020193590 Tetra- or hexa-hydroazepine compounds substituted at the 4 position with benzofur-7-yl, indol-7-yl, or benzo(b)thiophen-7-yl; antidepressants
12/19/2002	US20020193589 Mercaptoacetylamide derivatives, a process for their preparation and their use
12/19/2002	US20020193578 Compounds having activity as inhibitors of cytochrome P450RAI
12/19/2002	US20020193576 Mixture for use in the prevention and treatmenyt of infection
12/19/2002	US20020193571 Wsx receptor agonist antibodies
12/19/2002	US20020193561 P53 protein variants and therapeutic uses thereof
12/19/2002	US20020193446 Compounds and methods for the inhibition of the expression of VCAM-1
12/19/2002	US20020193445 Controlled release for fast peak plasma concentration of the active metabolite desglymidodrine; treating orthostaic hypotension and/or urinary incontinence
12/19/2002	US20020193444 Composition
12/19/2002	US20020193442 Method and compositions for the treatment or amelioration of female sexual dysfunction
12/19/2002	US20020193441 Prostanoid therapies for the treatment of glaucoma
12/19/2002	US20020193440 Liothyronine sodium and levothyroxine sodium combination
12/19/2002	US20020193439 90-95% eicosapentaenoic acid (EPA) and < 5% of docosahexaenoic acid (DHA); treating psychiatric or central nervous disorders
12/19/2002	US20020193438 Aripiprazole oral solution
12/19/2002	US20020193435 Nitroglycerin-menthol potentiation for treatment of angina
12/19/2002	US20020193434 Stilbene derivative and a platinum coordination compound
12/19/2002	US20020193433 Administering a patient a halogenated 2-phenyl-1,2-ethanediol dicarbamate enantiomer or enantiomeric mixture for the prevention or treatment of bipolar disorder
12/19/2002	US20020193432 Useful as modulators of the interaction between the receptor for advanced glycated end product and its ligands
12/19/2002	US20020193431 Administration of an effective amount of 15-epi-16-(para-fluoro)-phenoxy-lipoxin A4, Lipoxin-A4, 15-epi-lipoxin4 or 15-R/S-methyl-lipoxin4 or salts, esters, amides, carboxylic acids or prodrugs to treat angiogenesis
12/19/2002	US20020193430 Correcting polymorphic metabolic dysfunction with (-)- hydroxycitric acid
12/19/2002	US20020193429 Methods for treating neuropsychiatric disorders
12/19/2002	US20020193427 A prostanoic acid derivative as c-c chemokine synthesis inhibitor and useful for the treatment of circulatory diseases, inflammation, allergic and renal diseases
12/19/2002	US20020193425 Cancer chemopreventative compounds and compositions and methods of treating cancers
12/19/2002	US20020193424 Human cancerous cell anti-proliferation and survival inhibition agent
12/19/2002	US20020193422 Anthranilamides and methods of their use
12/19/2002	US20020193420 Neurotrophic, low molecular weight, small molecule heterocyclic ketone or thioester compounds are nonimmunosuppressive, has an affinity for FKBP type immunophilins
12/19/2002	US20020193419 Amino acid derivatives of triptolide compounds as immune modulators and anticancer agents
12/19/2002	US20020193418 Methods of using and preparing thiolutin dioxide
12/19/2002	US20020193416 Synergistic tumorcidal response induced by histamine
12/19/2002	US20020193415 Phenylindoles for the treatment of HIV
12/19/2002	US20020193414 Adamantane derivatives
12/19/2002	US20020193413 Use of panaverium bromide for preventing cell proliferation and diseases caused thereby in the liver and digestive tract
12/19/2002	US20020193412 Compounds and compositions for treating tissue ischemia
12/19/2002	US20020193410 Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans
12/19/2002	US20020193409 Prodrugs of anticancer agents employing substituted aromatic acids
12/19/2002	US20020193408 As anti-diarrheal and gastrointestinal anti-spasmodic agents
12/19/2002	US20020193406 Novel compound
12/19/2002	US20020193405 For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases
12/19/2002	US20020193404 Use of bicyclic heterocycles for the treatment and prevention of arterial thrombotic disease
12/19/2002	US20020193403 Administering retinoic acid receptors (RAR) antagonist or an RAR inverse agonist for therapy of hyperlipidemia in mammal
12/19/2002	US20020193399 N-arylsulfonyl aryl aza-bicyclic derivatives as potent cell adhesion inhibitors
12/19/2002	US20020193397 Nasal delivery of apomorphine
12/19/2002	US20020193396 Sulfonamido ether substituted imidazoquinolines
12/19/2002	US20020193395 Methods and compositions to treat glycosaminoglycan-associated molecular interactions
12/19/2002	US20020193394 Compounds for treating inflammatory diseases
12/19/2002	US20020193393 For therapy of respiratory tract diseases
12/19/2002	US20020193392 For therpay of respiratory disease is asthma or chronic obstructive pulmonary disease
12/19/2002	US20020193391 Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects

1 ... 5614 5615 5616 5617 5618 5619 5620 5621 5622 5623 5624 5625 5626 5627 5628 5629 5630 5631 5632 5633 5634 ... 7860